Characteristics of invasive fungal infection in critical patients of the altitude with septic shock.
DOI:
https://doi.org/10.35434/rcmhnaaa.2022.154.1697Keywords:
Invasive Fungal Infections, Shock Septic, Altitude, PeruAbstract
Introduction: In the ICU, 19% have fungi, 23% develop septic shock. Candida albicans the most frequent. The most commonly used antifungal is fluconazole. Objectives: In high altitude residents with septic shock (SS) we will describe: Characteristics, evolution and sensitivity of invasive fungal infection (IFI) and we will contrast them with those published at sea level. The study: Retrospective and transversal. We analyzed blood cultures of adults with SS and IFIs in an ICU at 3,250 meters of altitude, for 7 years.
Findings: 123 samples. The IFIs increased 3.6 for candida albicans. Women with 74 years was frequent. BGN represented 52.88%, BGP 37.9% and fungi 9.22%. Candida albicans 79.67% with sensitivity greater than 90% for Voriconazole, Amphotericin B and Fluconazole. Conclusions: IFIs with SS were caused by candida albicans, IFIs increased, there is adequate sensitivity to antifungals. At high altitudes there is a higher frequency of females, higher average age, and good sensitivity to fluconazole.
Downloads
Metrics
References
Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13.
Arendrup MC, Boekhout T, Akova M, Meis JF, Cornely OA, Lortholary O, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2014;20(Suppl 3):76-98.
Bassetti M, Azoulay E, Kullberg BJ, Ruhnke M, Shoham S, Vazquez J, et al. EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group. Clin Infect Dis Off Publ Infect Dis Soc Am. 2021;72(Suppl 2):S121-7.
Ayats J, Martín-Mazuelos E, Pemán J, Quindós G, Sánchez F, García-Rodríguez J, et al. Recomendaciones sobre el diagnóstico de la enfermedad fúngica invasora de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Actualización 2010. Enfermedades Infecc Microbiol Clínica [Internet]. 2011 [citado 28 de noviembre de 2021];29(1):39.e1-39.e15. Disponible en: https://www.elsevier.es/es-revista-enfermedades-infecciosas-microbiologia-clinica-28-articulo-recomendaciones-sobre-el-diagnostico-enfermedad-S0213005X10004027
Alvarez-Lerma F, Martínez MP, Cerdá EC, Bermejo B, Gil CL, Olaechea P. Colonización y/o infección por hongos en unidades de cuidados intensivos: Estudio multicéntrico de 1.562 pacientes. Med Clínica. 2003;121(5):161-6.
Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323-9.
Gourang P, David S, Marc S, Christopher C, Thomas L, Nimish P. The Effect of Time to Antifungal Therapy on Mortality in Candidemia Associated Septic Shock. Am J Ther. 2009;16(6):508-11.
Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, et al. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006). Crit Care Med. 2009;37(5):1612-8.
Leroy O, Mira JP, Montravers P, Gangneux JP, Lortholary O, AmarCand Study Group. Comparison of albicans vs. non-albicans candidemia in French intensive care units. Crit Care Lond Engl. 2010;14(3):R98.
Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;54(12):1739-46.
Serrano R, Gimeno A, Plumed L, Pemán J, Álvarez B, Plazas J, et al. Perfil epidemiológico y patrón de sensibilidad de aislamientos causantes de infección fúngica invasora frente a aislamientos fúngicos de colonización en pacientes críticos no neutropénicos. Rev Iberoam Micol. 2013;30(1):14-20.
Bassetti M, Righi E, Ansaldi F, Merelli M, Trucchi C, Cecilia T, et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med. 2014;40(6):839-45.
Nucci M, Queiroz-Telles F, Tobón AM, Restrepo A, Colombo AL. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;51(5):561-70.
Cortés JA, Jaimes JA, Leal AL. Incidence and prevalence of candidemia in critically ill patients in Colombia. Rev Chil Infectologia Organo Of Soc Chil Infectologia. 2013;30(6):599-604.
Ortíz Ruiz G, Osorio J, Valderrama S, Álvarez D, Elías Díaz R, Calderón J, et al. Risk factors for candidemia in non-neutropenic critical patients in Colombia. Med Intensiva. 2016;40(3):139-44.
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-77.
Ministerio de Salud. Resolución Ministerial N° 489-2005-MINSA. MINSA. 2005;031:01.
Tinoco-Solórzano A, Estrada VHN, Vélez-Páez JL, Franco DM, Soto AV, Villacorta-Córdova F, et al. Medicina intensiva en la altitud. Revision de alcance. Intensivos. 2020;13(4):218-25.
Tinoco-Solórzano A, Chumbes Perez J, Molano Franco D, Vélez Paez JL, Viruez Soto A. Perfil bacteriano del shock séptico en una unidad de cuidados intensivos de la altitud del seguro social del Perú. Rev Bionatura. 2021;6(4):2233-41.
Duque CM, Sanchez DM, Gaviria A, Vallejo Acosta A, Gómez B, Gómez OM, et al. Caracterización de Candida spp. aisladas a partir de urocultivos en la ciudad de Medellín. Infectio [Internet]. diciembre de 2020 [citado 5 de abril de 2022];24(4):217-23. Disponible en: http://www.scielo.org.co/scielo.php?script=sci_abstract&pid=S0123-93922020000400217&lng=en&nrm=iso&tlng=es
Voss A, Meis JF, Hoogkamp-Korstanje JA. Fluconazole in the management of fungal urinary tract infections. Infection. agosto de 1994;22(4):247-51.
González-Pedraza Avilés A, Luís Hernández R, Luna Ávila J, Dávila Mendoza R, Ortiz Zaragoza C. Infección de vías urinarias por especies de Candida. Aten Primaria [Internet]. julio de 2006 [citado 5 de abril de 2022];38(3):147-53. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7679930/
Rodriguez L, Bustamante B, Huaroto L, Agurto C, Illescas R, Ramirez R, et al. A multi-centric Study of Candida bloodstream infection in Lima-Callao, Peru: Species distribution, antifungal resistance and clinical outcomes. PloS One. 2017;12(4):e0175172.
Zubieta-Calleja G, Zubieta-De Urioste N. Longevidad extendida en la altura: Beneficios de la exposición a la hipoxia crónica. Univ J Health Sci. 2020;2(2):80-90.
Alvarez C, Cortes J, Arango Á, Correa C, Leal A. Resistencia Antimicrobiana en Unidades de Cuidado Intensivo de Bogotá, Colombia, 2001-2003. Rev Salud Pública. 2006;8(1):86-101.
Linares Contreras E, Pereira Alagon M. Perfil microbiologico y de sensibilidad a los antibioticos en dos hospitales de alta complejidad del seguro social de salud del Perú. IETSI. 2018;4(1):1-6.
Bustamante B, Martins MA, Bonfietti LX, Szeszs MW, Jacobs J, Garcia C, et al. Species distribution and antifungal susceptibility profile of Candida isolates from bloodstream infections in Lima, Peru. J Med Microbiol. junio de 2014;63(Pt 6):855-60.
Snydman DR. Shifting patterns in the epidemiology of nosocomial Candida infections. Chest. mayo de 2003;123(5 Suppl):500S-3S.
Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, National Nosocomial Infections Surveillance System Hospitals. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis Off Publ Infect Dis Soc Am. 1 de septiembre de 2002;35(5):627-30.
Garnacho-Montero J, Díaz-Martín A, Ruiz-Pérez De Piappón M, García-Cabrera E. Infección fúngica invasiva en los pacientes ingresados en las áreas de críticos. Enfermedades Infecc Microbiol Clínica [Internet]. 1 de junio de 2012 [citado 22 de noviembre de 2021];30(6):338-43. Disponible en: https://www.sciencedirect.com/science/article/pii/S0213005X12001206
Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 17 de abril de 2003;348(16):1546-54.
Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsåker T, Gaustad P, et al. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol. junio de 2006;44(6):1977-81.
Arendrup MC, Fuursted K, Gahrn-Hansen B, Schønheyder HC, Knudsen JD, Jensen IM, et al. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. mayo de 2008;14(5):487-94.
Bouza E, Muñoz P. Epidemiology of candidemia in intensive care units. Int J Antimicrob Agents. noviembre de 2008;32 Suppl 2:S87-91.
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA [Internet]. 2016 [citado 27 de enero de 2022];315(8):801-10. Disponible en: https://doi.org/10.1001/jama.2016.0287
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Amílcar Tinoco-Solórzano, Guillermo Ortiz Ruiz, Felipe de Jesús Montelongo, Ignacio Granda Luna, Armin Quispe Cornejo, Maricela Quispe-Montero
This work is licensed under a Creative Commons Attribution 4.0 International License.
